figure
posted on 2023-06-13, 14:20 authored by Kazunori Aoki, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi, Etsuko Fujii, Takashi Nishizawa, Hironori Fukuda, Kana Ohashi, Kosuke Arai, Yukihiro Mizoguchi, Yukihiro Yoshida, Shun-ichi Watanabe, Makiko Yamashita, Shigehisa Kitano, Hiromi Sakamoto, Yuki Nagata, Risa Mitsumori, Kouichi Ozaki, Shumpei Niida, Yae Kanai, Akiyoshi Hirayama, Tomoyoshi Soga, Toru Maruyama, Keisuke Tsukada, Nami Yabuki, Mei Shimada, Takehisa Kitazawa, Osamu Natori, Noriaki Sawada, Atsuhiko Kato, Teruhiko Yoshida, Kazuki Yasuda, Hideaki Mizuno, Hiroyuki Tsunoda, Atsushi Ochiai Immune cell compositions in LUAD and LUSQ; NAT (n = 157), LUAD (n = 85), LUSQ (n = 50), other types of lung cancer (n = 21). A, Percentages of immune cells per CD45+ cells (�45) in NSCLC and NATs. B, Percentages of CD4+ T-cell subsets per total CD4+ T cells for LUAD and LUSQ. C, Percentages of CD8+ T-cell subsets per total CD8+ T cells. D, Percentages of myeloid cell subsets per total myeloid cells. E and F, Relationships of immune cell types to clinicopathologic factors. Cells in the matrix represent log10 (Kruskal–Wallis P value) between �45 of immune cell compositions and clinicopathologic factors in LUAD (E) and LUSQ (F). Heat maps showing Spearman correlations between 23 immune cell types. Cell populations were clustered using hierarchical clustering in LUAD (G) and LUSQ (H).
Funding
Japan Agency for Medical Research and Development (AMED)
National Cancer Center Japan (NCC)
MEXT | Japan Society for the Promotion of Science (JSPS)
History
ARTICLE ABSTRACT
The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.